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Abstract
Background: Hepatocellular carcinoma (HCC) usually has a dismal prognosis because of its limited response to current
pharmacotherapy and high metastatic rate. Sulfated oligosaccharide has been confirmed as having potent antitumor
activities against solid tumors. Here, we explored the preclinical effects and molecular mechanisms of isomalto
oligosaccharide sulfate (IMOS), another novel sulfated oligosaccharide, in HCC cell lines and a xenograft model.
Methods: The effects of IMOS on HCC proliferation, apoptosis, adhesion, migration, and invasiveness in vitro were
assessed by cell counting, flow cytometry, adhesion, wound healing, and transwell assays, respectively. The roles of
IMOS on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals.
Total and phosphorylated protein levels of AKT, ERK, and JNK as well as total levels of c-MET were detected by
Western blotting. IMOS-regulated genes were screened by quantitative reverse-transcription PCR (qRT-PCR) array in
HCCLM3-red fluorescent protein (RFP) xenograft tissues and then confirmed by qRT-PCR in HepG2 and Hep3B cells.
Results: IMOS markedly inhibited cell proliferation and induced cell apoptosis of HCCLM3, HepG2, and Bel-7402
cells and also significantly suppressed cell adhesion, migration, and invasion of HCCLM3 in vitro. At doses of 60
and 90 mg/kg/d, IMOS displayed robust inhibitory effects on HCC growth and metastasis without obvious side
effects in vivo. The levels of pERK, tERK, and pJNK as well as c-MET were significantly down-regulated after
treatment with 16 mg/mL IMOS. No obvious changes were found in the levels of pAkt, tAkt, and tJNK. Ten
differentially expressed genes were screened from HCCLM3-RFP xenograft tissues after treatment with IMOS at a
dose of 90 mg/kg/d. Similar gene expression profiles were confirmed in HepG2 and Hep3B cells after treatment
with 16 mg/mL IMOS.
Conclusions: IMOS is a potential anti-HCC candidate through inhibition of ERK and JNK signaling independent of
p53 and worth studying further in patients with HCC, especially at advanced stages.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer and the third leading cause of cancer-
related death globally [1]. As indicated in statistics, the
disease is diagnosed in 30% to 40% of all patients at
early stages and about 20% of all patients are amenable
to curative therapies, such as resection, liver transplanta-
tion, and radiofrequency ablation [2,3]. Five-year survival
rates of up to 60% to 70% have been achieved in well-
selected patients [2]. However, HCC at advanced stages
usually carries a dismal prognosis because of liver dys-
function, lack of effective treatment options, and a high
metastatic rate [4,5]. Therefore, it is urgent to explore
new therapeutic options for patients with advanced
HCC.
Heparanase inhibitor has recently become an attrac-
tive agent for highly malignant tumors, due to its
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any medium, provided the original work is properly cited.antiangiogenic and antimetastatic activities [6-10]. Two
representatives, phosphomannopentaose sulfate (PI-88)
and oligomannurarate sulfate (JG3), were reported to
have inhibitory effects on tumor growth and metastasis
[11,12]. Phase 1 and 2 trials of PI-88 have been finished
and have shown potential antitumor effects [13-16].
Two distinctive differences in molecular structure
exist between isomalto oligosaccharide sulfate (IMOS)
and PI-88. IMOS is composed of four sulfated isomal-
tose molecules with a molecular weight <1500 Da,
whereas PI-88 is composed of five sulfated mannose
molecules with a molecular weight of 2100 to 2585 Da.
Such alterations in structure may affect its toxicity and
antitumor effects. In this report, we present our preli-
minary evidence of the effects of IMOS on experimental
HCC growth and metastasis.
Methods
IMOS
IMOS, with a patent (patent no. ZL2005 1 0002141.8)
granted by the State Food and Drug Administration of
China, is designed and successfully synthesized de novo
by Herbon Polysaccharide Bio-tech. Figure 1 shows the
chemical structure of IMOS. IMOS was dissolved in
Dulbecco modified Eagle medium (DMEM) containing
10% fetal bovine serum (FBS; Gibco BRL, Grand Island,
NY, USA), sterilized with a 0.22-μm filter (Millipore,
Billeria MA, USA), and reserved at a concentration of
320 mg/mL for in vitro assays. In a similar way, IMOS
was dissolved in saline under sterile conditions with a
concentration of 600 mg/mL for in vivo assays.
Cell lines
Four human hepatoma cell lines HepG2, Bel-7402,
Hep3B, HCCLM3, and its red fluorescent protein (RFP)-
expressing derivative, HCCLM3-RFP, were used in this
study [17]. HCCLM3, HCCLM3-RFP, and HepG2 were
cultured in DMEM, Hep3B in minimum essential med-
ium (MEM), and Bel-7402 cells in RPMI-1640, supple-
mented with 10% FBS containing 5% CO2 at 37°C.
Cell proliferation assay
Cell proliferation was assessed by the method described
p r e v i o u s l y[ 1 7 ] .I nb r i e f ,H C C L M 3 ,H e p G 2 ,a n dB e l -
7402 cells were seeded into 96-well plates at 2 × 10
3
cells/well. Twenty-four hours later, cells were exposed
to IMOS at doses ranging from 0 to 64 mg/mL. On
days 1, 2, 3, 4, and 5, cells were digested with pancreatic
enzymes including ethylenediaminetetraacetic acid
(EDTA) and washed with phosphate-buffered saline
(PBS). Cell numbers were then counted by the Coun-
tess™ automated cell counter (Life Technologies, CA).
Cell cycle and apoptosis assays
Cell cycle and apoptosis were detected using the
Annexin V-FITC Apoptosis Detection Kit™ according
to the manufacturer’s instructions (BD Pharmingen, San
Diego, CA). Briefly, HCCLM3, HepG2, and Bel-7402
cells were plated into 6-well plates at 4 × 10
5 cells/well.
After treatment with IMOS at 0, 2, 4, 16, 32, or 64 mg/
mL for 24 hours, the cells were fixed with ethanol and
stained with annexin V for early apoptosis assay by a
fluorescence-activated cell sorter (FACS) Calibur cyt-
o m e t e r( B DB i o s c i e n c e s ,S a nJ o s e ,C A ,U S A ) .I nt h e
same way, 72 hours after IMOS treatment, the cells
were stained with propidium Iodide (PI) for late apopto-
sis and cell cycle assays.
Cell adhesion assay
The 96-well flat-bottom plates were precoated with 50
μL/well of 1:8 PBS-diluted Matrigel at 4°C overnight.
After removing all coating solutions, the plates were
blocked with 150 μL of 1% bovine serum albumin for 1
hour at 37°C. Then, HCCLM3 cells were treated with 0,
16, 32, or 64 mg/mL IMOS for 4 hours, seeded into
Matrigel-coated wells at 5 × 10
4 cells/well, and incu-
bated for 2 hours at 37°C in 5% CO2. After extensive
washing, cells were fixed with 100 μL/well of 4% formal-
dehyde for 20 minutes and stained with a hematoxylin
solution for 10 minutes. The average numbers of adhe-
sion cells in four quadrants were counted by inverted
microscope.
Wound healing assay
Cell migration was analyzed by a wound healing assay.
When cells grew to 90% of confluency, a scratch wound
in the monolayer was made using a pipette tip. After
washing away all detached cells with PBS, the remaining
cells were treated with 0, 16, 32, or 64 mg/mL IMOS
and then the distances of wounds were measured by
microscope at 0, 24, and 48 hours after treatment. Cell
motility was evaluated the following formula: Cell moti-
lity = (distance24 or 48 hours -d i s t a n c e 0h o u r )/distance0
hour.
Invasion assay
Cell invasion was analyzed by a Transwell™ Permeable
Supports system (Corning, Inc., Corning, NY, USA)
Figure 1 Chemical structure of IMOS.R :S O 3Na or H
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cells were pretreated with 0, 16, 32, or 64 mg/mL IMOS
for 48 hours, and then seeded into the Matrigel-coated
upper insert at 8 × 10
4 cells/24-wells in medium supple-
mented with 1% serum. Medium containing 10% serum
was added to the well as a chemoattractant. Following a
culture of 48 hours, non-invading cells were removed
from the upper surface by wiping with a cotton swab.
The membrane was fixed with 4% formaldehyde for 15
minutes at room temperature. The invading cells were
stained with Giemsa (Sigma, Munich, Germany) for 25
minutes, and their numbers in 10 fields of each tripli-
cate filter were analyzed by inverted microscope.
Protein levels detected by Western blotting
Total and phosphorylated protein levels of AKT, ERK,
and JNK as well as total protein of c-MET in HepG2
and Hep3B cells were evaluated by Western blotting.
About 20 μg protein was extracted from sham-treated
and 16 mg/mL IMOS-treated cells, separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE), transferred onto polyvinylidene fluor-
ide membranes, and then reacted with primary rabbit
antibodies against total and phosphorylated AKT, ERK,
and JNK(1:500; Bioworld Tech, Minneapolis, MN, USA),
c - M E T( 1 : 1 0 0 0 ,E p i t o m i c s ,B u r l i n g a m e ,C A ,U S A )a n d
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
After being extensively washed with PBS containing
0.1% Triton X-100, the membranes were incubated with
alkaline phosphatase-conjugated goat anti-rabbit anti-
body for 30 minutes at room temperature. The bands
were visualized using 1-step™ NBT/BCIP reagents
(Thermo Fisher Scientific, Rockford, IL, USA) and
detected by the Alpha Imager (Alpha Innotech, San
Leandro, CA, USA).
Tolerable dose assay of IMOS in vivo
A dose-escalation strategy was used in male athymic
BALB/c mice (Institute of Materia, CAS, Shanghai,
China) to determine maximum tolerable dose of IMSO.
Eighty mice, aged 4 weeks, were divided into groups of
10 mice apiece, with each mouse intraperitoneally
injected with IMOS at a dose of 0, 30, 60, 90, 180, 360,
480, or 600 mg/kg/d, respectively. Mouse survival was
monitored every day. We planned to halt the dose esca-
lation would be halted if mice died. Serum was collected
for assays of hepatorenal function. Plasma was collected
for determining thrombocyte counts. Heart, liver, and
kidney tissues were subjected to hematoxylin and eosin
staining for pathologic examinations. The maximum
nonlethal dose was determined for the following in vivo
therapeutic study. All procedures were approved by the
Animal Care and Use Committee of Shanghai, China.
Antitumor growth and metastasis assays in vivo
Antitumor activities of IMOS in vivo were assessed
against HCCLM3-RFP xenografts. Three 4-week-old
male athymic BALB/c mice were injected subcuta-
neously with 1 × 10
7/0.2 mL of HCCLM3-RFP cells in
the right upper flank region to establish subcutaneous
xenograft models. Four weeks later, the tumors that had
grown to 1 cm in diameter were removed, cut into 1-
mm
3 pieces, and implanted into livers of another 24
mice to establish orthotopic xenograft models as
described previously [18]. Then, all mice were randomly
divided into four groups of six mice each and intraperi-
toneally injected with IMOS at 0, 30, 60, or 90 mg/kg/d
once daily for 30 consecutive days. Fluorescent images
of in situ tumor were taken once a week with the
mouse anesthetized with 50 mg/kg sodium pentobarbi-
tal. On day 30, all mice were sacrificed and tumor
volume was calculated using the formula V (mm
3)=
width
2 (mm
2) × length (mm)/2. Metastatic foci in lungs
and mesenteries were counted by fluorescent stereomi-
croscope (stereomicroscope: Leica MZ6; illumination:
Leica L5 FL; C-mount: 0.63/1.25; CCD: DFC 300FX).
Fluorescence area (AOI, pixel) was quantified by Image-
Pro Plus 6.0 (Media Cybernetics, Silver Spring, MD,
USA) as described previously [17].
IMOS-regulated genes detected by quantitative reverse-
transcription polymerase chain reaction (qRT-PCR) and
qRT-PCR array
Tumor tissues from mice treated with IMOS at a dose
of 0 or 90 mg/kg/d were enrolled for differentially
expressed gene analysis by RT Profiler PCR Arrays
(SABioscience, PAHS-027A, Frederick, MD, USA) and
performed by Kangchen Bio-tech (Shanghai, China).
The mRNA levels of differentially expressed genes in
HepG2 and Hep3B cells with 16-mg/mL IMOS treat-
ment were confirmed by qRT-PCR. Total RNA of cells
was extracted using RNeasy MinElute Cleanup Kit (Qia-
gen, Valencia, CA, USA). Then, 1.5 μg RNA was rever-
sely transcribed into first-strand cDNA using
SuperScript™ III Reverse Transcriptase (Invitrogen, NY,
USA). Primer sequences and amplification conditions
are listed in Additional file 1. The reactions were per-
formed on a DNA Engine Opticon system (MJ Research,
Reno, NV, USA) using SYBR
® Green PCR Master Mix
(Applied Biosystems). Following each cycle, SYBR green
fluorescence was monitored and the melting curve was
analyzed to ensure that a single PCR product was
obtained. Afterward, the size and specificity of ampli-
cons were confirmed by 2.5% agarose gel electrophor-
esis. All reactions were repeated in three separate runs
and evaluated with the Opticon Monitor software (Ver-
sion 1.02). GAPDH was used to normalize the samples.
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control in RNA extraction and in each run.
Statistical analysis
Statistical analysis was performed with SPSS 15.0 for
w i n d o w s( S P S S ,C h i c a g o ,I L ,U S A ) .Q u a n t i t a t i v ev a r i -
ables were expressed as means ± SD and analyzed by
ANOVA. Results were considered statistically significant
at P < 0.05.
Results
Inhibitory effects of IMOS on HCC proliferation
To explore the effects of IMOS on HCC proliferation,
HCCLM3, HepG2, and Bel-7402 cells were treated with
IMOS at doses ranging from 0 to 64 mg/mL. IMOS dra-
matically decreased cell numbers of all tested cell lines
in a dose-dependent manner, especially when exposed
to 16- and 64-mg/mL doses of IMOS (Figure 2A-C).
The inhibitory ratio of IMOS on cell proliferation was
significantly increased from 23.3% ± 1.9% to 99.06% ±
4.6% in HCCLM3 cells, from 24.4% ± 9.5% to 98.5% ±
9.8% in HepG2 cells, and from 27.8% ± 1.2% to 91.4% ±
1.6% in Bel-7402 cells during a 5-day treatment (Figure
2 D ) .T h ed a t as u g g e s tI M O Sh a sr o b u s ts u p p r e s s i v e
effects on HCC proliferation.
Cell cycle arrest and apoptosis induced by IMOS
To address whether proliferation inhibition of IMOS
was attributed to cell cycle arrest, cell cycle phases of
H C C L M 3 ,H e p G 2 ,a n dB e l - 7402 cells were next ana-
lyzed by flow cytometry. As expected, cell numbers at
the S and G2/M phases were significantly decreased,
whereas cell numbers at the G0/G1 phase were mark-
edly increased after IMOS treatment in a dose-
Figure 2 Effects of IMOS on proliferation of HCC cells. Proliferation of HCCLM3, HepG2, and Bel-7402 cells was significantly inhibited by IMOS
in a dose-dependent manner, especially when exposed to 16- and 64-mg/mL doses of IMOS. (A-C) Growth curve of HCCLM3, HepG2, and Bel-
7402 cells, respectively, treated with IMOS at doses ranging from 0 to 64 mg/mL for 5 consecutive days. (D) Inhibition ratio of proliferation of
HCCLM3, HepG2, and Bel-7402 cells was markedly increased after ≥4 mg/mL IMOS treatment.
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Page 4 of 11dependent manner (Figure 3A-C). To further investi-
gate whether cell apoptosis was also involved in prolif-
eration inhibition caused by IMOS, early and late
apoptotic cells were monitored by annexin V and PI
staining, respectively. The percent of early apoptosis
cells increased significantly after ≥4 mg/mL IMOS
treatment (Figure 3D-F). The percent of late apoptotic
cells was statistically higher in HCCLM3, HepG2, and
Bel-7402 cells after ≥16 mg/mL IMOS treatment (Fig-
ure 3G-I).
Adhesion, migration, and invasiveness of HCCLM3
inhibited by IMOS in vitro
To detect antitumor activities of IMOS on HCCLM3,
cell adhesion, wound healing, and transwell assays were
performed after treatment with IMOS at doses of 0, 16,
32, and 64 mg/mL, respectively. HCCLM3 adhesion was
markedly inhibited by IMOS at doses of 16, 32, and 64
mg/mL as compared with sham treatment (Figure 4A
and 4B). HCCLM3 migration was significantly sup-
pressed in a dose- and time-dependent manner (Figure
Figure 3 Cell cycle arrest and apoptosis induced by IMOS in HCCLM3, HepG2, and Bel-7402 cells. (A-C) Cell numbers at G2/M and S
phases decreased dramatically in HCCLM3, HepG2, and Bel-7402 cells in a dose-dependent manner. (D-F) After exposure to 4, 16, and 64 mg/
mL IMOS for 24 hours, the number of apoptotic cells of HCCLM3, HepG2, and Bel-7402 were significantly increased as compared with control
cells. (G-I) After treatment for 48 hours, IMOS significantly induced apoptotic death in HCCLM3, HepG2, and Bel-7402 cells at doses from 16 to 64
mg/mL.
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Page 5 of 11Figure 4 Inhibitory effects of IMOS on HCCLM3 cell adhesion, migration, and invasiveness. (A) Representative images of adhesion cell
(×200) and (B) HCCLM3 adhesion was markedly inhibited by IMOS at doses of 16, 32, and 64 mg/mL as compared with sham treatment. (C)
Representative images of migration distances (×100) and (D) HCCLM3 migrations began to be significantly inhibited by 16 mg/mL IMOS after a
24-hour treatment, and by 4 mg/mL IMOS after a 48-hour treatment (P < 0.01). (E) Representative images of transmembrane cells (×200) after
treatment with 0, 16, 32, and 64 mg/mL IMOS. (F) Invasiveness of HCCLM3 was inhibited by IMOS in a dose-dependent manner.
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cells after IMOS treatment with doses of 0, 16, 32, and
64 mg/mL were 174.67 ± 5.69, 84.33 ± 18.15, 69 ±
18.52, and 17 ± 5.57, respectively (Figure 4E and 4F).
These data demonstrate that IMOS is a potent inhibitor
of cell adhesion, migration, and invasiveness of
HCCLM3.
Maximum tolerable dose of IMOS in vivo
To determine the maximum tolerable dose for in vivo
therapeutic study, IMOS with an initial dose of 30 mg/
kg/d was injected intraperitoneally into mice once daily
in an escalating-dose schedule. No mouse death was
observed during a 30-day treatment with IMOS given at
30, 60, and 90 mg/kg/d. On day 30, the numbers of
thrombocytes in mice treated with IMOS at 0, 30, 60,
and 90 mg/kg/day were 1164 ± 183, 1089 ± 210, 1170 ±
224, and 1049 ± 258 × 10
9/L, respectively. No obvious
thrombocytopenia was found after IMOS treatment. No
significant abnormalities were found in these mice as
evaluated by body weights (Additional file 2), hepatore-
nal function (Additional file 3), and pathologic examina-
tions of heart, liver, and kidney tissues (Additional file
4). However, mice began to die at day 6 at an IMOS
dose of 180 mg/kg/d. Therefore, IMOS at a dose of ≤90
mg/kg/d was well tolerated by athymic BALB/c mice.
HCC growth and metastasis suppressed by IMOS in
xenograft models
To determine its effects on HCC progression, IMOS was
intraperitoneally given to HCCLM3 xenograft mice at
doses of 30, 60 and 90 mg/kg/d. In accord with the
results in vitro, IMOS inhibited tumor growth and
metastasis of HCCLM3 xenograft in a dose-dependent
pattern (Figure 5A-E). Tumor growth was observed to
be dramatically suppressed by IMOS at 90 mg/kg/d
after a 3-week treatment (Figure 5A). On day 30, tumor
volumes in 30, 60 and 90 mg/kg/d IMOS-treated mice
were 1.24 ± 0.28 cm
3,1 . 0 1±0 . 2 2c m
3,a n d0 . 8±0 . 1
cm
3, respectively, much smaller than the volume in
sham-treated mice (1.91 ± 0.27 cm
3, P < 0.001; Figure
5B). Furthermore, metastatic foci in lung and mesentery
in mice treated with IMOS doses of 30, 60, and 90 mg/
kg/d were 3327 ± 137 and 1547 ± 56,1335 ± 115 and 72
± 15, 1120 ± 105 and 60 ± 11, respectively, which were
also statistically smaller than seen in sham-treated mice
(3506 ± 125 and 1764 ± 78; Figure 5C-E). The results
suggest that IMOS has potent suppressive activities not
only on HCC growth but also on HCC metastasis.
Signal pathways and gene expressions regulated by IMOS
To understand underlying mechanisms, total and phos-
phorylated protein levels of AKT, ERK, and JNK as well
as c-MET were analyzed in sham-treated and 16-mg/mL
IMOS-treated HepG2 and Hep3B cells. The levels of
pERK, tERK, and pJNK were significantly down-regu-
lated in both cell lines, whereas the level of c-MET was
markedly down-regulated only in HepG2 cells. No
obvious changes were found in the protein levels of
pAkt, tAkt, and tJNK (Figure 6A). Furthermore, 10 dif-
ferentially expressed genes were found in 90-mg/kg/d
IMOS-treated xenograft tissues as compared with sham-
treated tissues. Among them, Bcl-2, BIRC/survivin,
PCNA, CDK1/CDK2,a n dPRC1 were down-regulated
more than 2-fold, whereas BAI-1, TP73,a n dMDM2
were up-regulated more than 2-fold (Figure 6B). Except
for RPRM/Reprimo and interferon b (IFN-b), similar
expression profiles were confirmed in IMOS-treated
HepG2 and Hep3B cells as compared with HCCLM3
xenograft (Figure 6C and 6D).
Discussion
HCC usually has a limited response to current pharma-
cotherapy. It has been reported that MHCC97L and
HepG2 cells surviving oxaliplatin treatment show
enhanced migration and invasion in vitro and increase
metastasis to the lung when reinoculated into nude mice
[19]. Similar results have been observed in our previous
study that IFN-a had contrasting aspects of consistently
suppressing HCC growth but also promoting tumor
metastasis capacity [20]. Therefore, it is urgent to investi-
gate new agents with robust inhibitory effects on both
HCC growth and metastasis. Fortunately, small molecu-
lar agents of sulfated oligosaccharides were confirmed to
have potent antitumor activities against primary tumor
growth and metastasis [11,12]. Therefore, IMOS was
assumed to have similar activities against HCC progres-
sion. As expected, IMOS dramatically inhibited cell pro-
liferation and induced cell cycle arrest and apoptosis in
three tested HCC cell lines. Furthermore, suppressive
effects on cell adhesion, motility, and invasiveness of
HCCLM3 in vitro as well as tumor growth and metastasis
of HCCLM3 xenograft in vivo were obviously achieved
by IMOS treatment in a dose-dependent manner. These
findings suggest that IMOS is a possible novel compound
to be used against progression of HCC.
According to previous studies, sulfated oligosacchar-
ides were thought to suppress tumor angiogenesis,
growth, and metastasis primarily by their competitive
inhibition of the cleavage of heparan sulfate-growth fac-
tor complex, thus reducing the release of growth factors,
such as vascular endothelial growth factor and basic
fibroblast growth factor from the microenvironmental
matrix [21]. However, many direct actions of IMOS on
HCC cells in vitro cannot be satisfactorily explained by
its inhibition of heparanase activities. Therefore, we
focused our mechanism studies on cell proliferation and
apoptosis regulation in this study.
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Page 7 of 11Figure 5 Effects of IMOS on tumor growth and metastasis of HCCLM3-RFP xenograft. (A) HCC growth was dramatically suppressed by
IMOS treatment, especially at doses of 60 and 90 mg/kg/d after 3 weeks. (B) Tumor volumes in mice treated with IMOS at 30, 60, and 90 mg/
kg/d were markedly smaller than the volume in sham-treated mice on day 30 (P < 0.01). (C-E) Lung and mesentery metastases were significantly
inhibited by IMOS at doses of 60 and 90 mg/kg/d (P < 0.01 for both). (C) Representative fluorescent images and (D and E) statistical results of
metastatic foci in lung and mesentery (P < 0.01).
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JNK signaling pathways have important roles in can-
cerous cell proliferation, cell cycle, and apoptosis regu-
lation in a p53-dependent or -independent manner
[22-24]. Dysfunctions of those pathways are common
events in tumorigenesis and progression in many types
of cancers, including HCC [25,26]. Therefore, HepG2,
a HCC cell line with wild-type p53, and Hep3B, a cell
line with mutant p53, were used for further study to
elucidate the mechanism of IMOS. Our preliminary
results from Western blots revealed that ERK and JNK
but not Akt signaling pathways were significantly
inhibited by IMOS in both cell lines, whereas c-MET,
a well-known p53 transcriptional target, was only
down-regulated in HepG2 [27]. All those results indi-
cated that ERK/JNK signaling pathways were involved
in IMSO-mediated p53 activity in HepG2, but not in
Hep3B.
Ten differentially expressed genes were screened
from HCCLM3-RFP xenografts. Eight of them were
confirmed in IMOS-treated HepG2 and Hep3B cells.
Because similar profiles of most differentially
expressed genes were found in both HepG2 and
Hep3B cells, IMOS may inhibit cell proliferation and
induce cell apoptosis of HCC in a p53-independent
manner. Among them, BAI-1 and TP73 were signifi-
cantly up-regulated, whereas Bcl-2, BIRC5/survivin,
PCNA,a n dCDK1/CDK2 were markedly down-regu-
lated. Our findings are consistent with previous obser-
vations that Bcl-2, BIRC5/survivin,a n dBAI-1 were the
mediators of cell cycle arrest and apoptosis regulation
[28-30]. Ectopic expression of PCNA was able to sup-
press cell apoptosis [31], thus decreased expression of
PCNA in HCC after IMOS treatment was probably
able to induce cell apoptosis. Furthermore, as an
apoptosis-induced gene [32], enhanced expression of
P73 in IMOS-treated tissue may also promote HCC
apoptosis.
Conclusions
IMOS, a novel sulfated oligosaccharide, at doses of ≤90
mg/kg/d exhibited potent antitumor effects on experi-
mental HCC growth and metastasis. It should be a pro-
mising anti-HCC agent and worth further studies in
patients with HCC, especially disease at advanced
stages.
Figure 6 Signaling pathways and gene expressions regulated by IMOS.( A )p E R K ,t E R K ,a n dp J N Kw e r es i g n i f i c a n t l yd o w n - r e g u l a t e db y
IMOS in both HepG2 and Hep3B cells, whereas c-MET was markedly down-regulated only in HepG2 cells. No obvious changes were found in
protein levels of pAkt, tAkt, and tJNK. (B) Ten genes were significantly regulated by IMOS in HCCLM3-RFP xenografts. Among them, Bcl-2, BIRC5/
survivin, PCNA, CDK1/CDK2, and PRC1 were down-regulated, and BAI-1, TP73, and MDM2 up-regulated by more than twice. (C,D) Except for RPRM/
Reprimo and IFN-b, similar expression profiles were confirmed in IMOS-treated HepG2 and Hep3B cells.
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Additional file 1: Primer sequences and amplification conditions of
qRT-PCR.
Additional file 2: Body weights of nude mice after IMOS treatment
(g, ¯ x± SD).
Additional file 3: Hepatorenal parameters of nude mice after IMOS
treatment (¯ x ± SD).
Additional file 4: Pathologic examinations of heart, liver, and
kidney tissues after treatment with IMOS.
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